Projects Project Ongoing 5 Members TRANSLOCK-ER – Sec61 inhibitors for Oncology Caroline Demangel (PI) Multiple Myeloma (MM) is an incurable malignancy characterized by the uncontrolled expansion of plasma cells in the bone marrow. While proteasome inhibitors like bortezomib efficiently halt MM progression drug resistance inevitably develop, and novel […] Project Ongoing 8 Members BURULI Path: the subversive role of mycolactone Caroline Demangel (PI) Mycobacterium ulcerans causes Buruli ulcer, a neglected tropical skin disease manifesting as chronic wounds that can leave victims with major, life-long deformity and disability. Differently from other mycobacteria, including the related M. tuberculosis and […]
Publications Download 2023 Domenger A, Ricci D, Mayau V, Majlessi L, Marcireau C, Dadaglio G, Demangel C, Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma., Front Oncol 2023 ; 13(): 1110916.